Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Boris Freidlin

Showing results (101-110 of 118) with videos related to

Pageof 12
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 8, 2012
Randomized phase II trial designs with biomarkersBoris Freidlin, Lisa M McShane, Mei-Yin C Polley, et al.
Clinical Trials (London, England)|August 14, 2008
Comments on 'maintaining confidentiality of interim data to enhance trial integrity and credibility' by TR Fleming et alEdward L Korn, Sally Hunsberger, Boris Freidlin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 20, 2005
Preliminary data release for randomized clinical trials of noninferiority: a new proposalEdward L Korn, Sally Hunsberger, Boris Freidlin, et al.
Cancer Journal (Sudbury, Mass.)|July 24, 2019
Biostatistical and Logistical Considerations in the Development of Basket and Umbrella Clinical TrialsLaura M Yee, Lisa M McShane, Boris Freidlin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 22, 2007
Proposal for the use of progression-free survival in unblinded randomized trialsBoris Freidlin, Edward L Korn, Sally Hunsberger, et al.
Clinical Trials (London, England)|September 4, 2016
Comparison of futility monitoring guidelines using completed phase III oncology trialsQiang Zhang, Boris Freidlin, Edward L Korn, et al.
Statistics in Medicine|September 30, 2014
Two-stage adaptive cutoff design for building and validating a prognostic biomarker signatureMei-Yin C Polley, Eric C Polley, Erich P Huang, et al.
Bioinformatics (Oxford, England)|November 9, 2002
Methods for assessing reproducibility of clustering patterns observed in analyses of microarray dataLisa M McShane, Michael D Radmacher, Boris Freidlin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 30, 2005
Design issues of randomized phase II trials and a proposal for phase II screening trialsLawrence V Rubinstein, Edward L Korn, Boris Freidlin, et al.
Journal of the National Cancer Institute|October 19, 2013
Statistical and practical considerations for clinical evaluation of predictive biomarkersMei-Yin C Polley, Boris Freidlin, Edward L Korn, et al.
Pageof 12

Showing results (101-110 of 118) with videos related to

Sort By:
Pageof 12
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 8, 2012
Randomized phase II trial designs with biomarkersBoris Freidlin, Lisa M McShane, Mei-Yin C Polley, et al.
Clinical Trials (London, England)|August 14, 2008
Comments on 'maintaining confidentiality of interim data to enhance trial integrity and credibility' by TR Fleming et alEdward L Korn, Sally Hunsberger, Boris Freidlin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 20, 2005
Preliminary data release for randomized clinical trials of noninferiority: a new proposalEdward L Korn, Sally Hunsberger, Boris Freidlin, et al.
Cancer Journal (Sudbury, Mass.)|July 24, 2019
Biostatistical and Logistical Considerations in the Development of Basket and Umbrella Clinical TrialsLaura M Yee, Lisa M McShane, Boris Freidlin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 22, 2007
Proposal for the use of progression-free survival in unblinded randomized trialsBoris Freidlin, Edward L Korn, Sally Hunsberger, et al.
Clinical Trials (London, England)|September 4, 2016
Comparison of futility monitoring guidelines using completed phase III oncology trialsQiang Zhang, Boris Freidlin, Edward L Korn, et al.
Statistics in Medicine|September 30, 2014
Two-stage adaptive cutoff design for building and validating a prognostic biomarker signatureMei-Yin C Polley, Eric C Polley, Erich P Huang, et al.
Bioinformatics (Oxford, England)|November 9, 2002
Methods for assessing reproducibility of clustering patterns observed in analyses of microarray dataLisa M McShane, Michael D Radmacher, Boris Freidlin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 30, 2005
Design issues of randomized phase II trials and a proposal for phase II screening trialsLawrence V Rubinstein, Edward L Korn, Boris Freidlin, et al.
Journal of the National Cancer Institute|October 19, 2013
Statistical and practical considerations for clinical evaluation of predictive biomarkersMei-Yin C Polley, Boris Freidlin, Edward L Korn, et al.
Pageof 12